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Homoarginine (hArg) has been shown to be of prognostic value in patients with chronic left
heart failure. The present study aims to assess the clinical utility and prognostic value of
hArg levels in patients with complex congenital heart disease (CHD).
Methods
Plasma hArg levels were measured in 143 patients with complex CHD and compared to clin-
ical status, echocardiographic and laboratory parameters as well as the occurrence of
adverse cardiac events.
Results
Median hArg levels were 1.5 μmol/l in CHD patients as compared to 1.70 μmol/l in healthy
controls (p = 0.051). Median hArg levels were lowest in patients with Fontan palliation
(1.27 μmol/l) and Eisenmenger physiology (0.99 μmol/l) and decreased with the severity of
adverse cardiac events with lowest values found in patients prior to death or overt heart fail-
ure (0.89 μmol/l). According to ROC analysis, the most important predictors of adverse car-
diac events were hArg levels (AUC 0.837, p<0.001, CI 0.726–0.947), NYHA class (AUC
0.800, p<0.001, CI 0.672–0.928) and NT-proBNP levels (AUC 0.780, p<0.001, CI 0.669–
0.891). The occurrence of overt heart failure or death due to progressive heart failure were
best predicted by NYHA class (AUC 0.945, p<0.001, CI 0.898–0.992), hArg levels (AUC
0.911, p<0.001, CI 0.850–0.971) and NT-proBNP levels (AUC 0.877, p<0.001, CI 0.791–
0.962), respectively.
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Conclusion
In patients with complex CHD, hArg levels can predict adverse cardiac events as reliably as
or even better than NT-proBNP levels and thus might be of prognostic value in this subset of
patients.
Introduction
Natriuretic peptides (NPs) such as BNP or NT-proBNP are known to be of diagnostic and
prognostic value in patients with congenital heart disease (CHD) [1–3]. Risk stratification
using NP levels in this subset of patients, however, may be challenging due to the heterogeneity
of malformations, the different pathophysiology (biventricular versus univentricular physiol-
ogy) and the presence of hypoxia (decreased oxygen saturation) [4,5]. Moreover, confounders
such as age, sex, renal dysfunction and obesity may further influence NP levels [6–8]. Since NP
are mainly secreted from the left ventricle due to increasing myocardial wall stress and thus
are “load-dependent”, medication also may alter NP levels. In CHD patients, the pathophysiol-
ogy of the underlying malformation plays an important role in the assessment of NP levels.
Patients with a systemic morphological right ventricle or univentricular physiology after the
Fontan procedure usually show lower NP levels than patients with biventricular physiology.
Nevertheless, BNP has been proven to predict mortality in adults with CHD [9].
Homoarginine (hArg) is an amino acid that plays an important role in nitric oxide (NO)
metabolism increasing the availability of NO by inhibiting the enzyme arginase to increase L-
arginine for NO production [10,11]. hArg itself may also serve as substrate for NO synthesis. It
has been shown that lack of NO is associated with endothelial as well as myocardial dysfunc-
tion [12,13]. There are two sources of homoarginine: a) synthesis from lysine in an “alternative
urea cycle” b) amidation of lysine by L-arginine:Glycine amidinotransferase [14]. Although
the mechanisms linking hArg to cardiovascular disease are not completely understood, previ-
ous studies in cardiovascular high risk patients as well as in patients with chronic left heart fail-
ure demonstrated that low hArg levels are associated with adverse cardiovascular outcomes
and all-cause mortality [14–16]. These results suggest that hArg may be an independent prog-
nostic marker in patients with cardiovascular disease and/or left heart failure.
To our knowledge, studies investigating hArg levels in CHD patients are lacking. However,
serum levels of asymmetrical dimethylarginine, a potent endogenous inhibitor of NO synthase
competing with arginine for NO synthase binding, were measured in adults with CHD dem-
onstrating to be more sensitive than NT-proBNP in detecting different stages of heart failure
in this cohort of patients [17]. Moreover, symmetrical dimethylarginine was found to be supe-
rior to NT-proBNP in detecting systemic ventricular dysfunction in CHD patients after atrial
repair for transposition of the great arteries [18]. Both studies demonstrate the potential diag-
nostic value of these markers, however, prognostic utility hasn’t been addressed.
The aim of the present study therefore was to analyse hArg levels in patients with complex
CHD in order to assess its clinical utility and prognostic value in this subset of patients.
Materials and methods
Patients
155 patients with various types of complex CHD were screened consecutively in our CHD out-
patient clinic between 22/12/2008 and 27/7/2015 to participate in the study. Complex CHD
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was defined as CHD of mostly great complexity according to ACC/AHA guidelines [19] thus
including patients after corrective surgery of congenital right heart disease (CRHD) such as
pulmonary atresia or tetralogy of Fallot, patients with a systemic morphological right ventricle
(SRV), patients with single ventricle physiology after Fontan palliation (FONT) and patients
with a non-corrected cyanotic heart defect or Eisenmenger physiology (EIS). All other patients
with CHD of simple or moderate complexity were not approached for participation. 12/155
patients with complex CHD could not be included in the analysis due to various reasons (3
patients were lost to follow-up, 2 patients refused to participate, 7 patients had missing relevant
laboratory or echocardiographic parameters) giving a drop-out rate of 7.7%.
Finally, a total of 143 patients with complex CHD were enrolled in the study. Mean age was
27.5 ± 12.0 years (range 11–73 years). 64 patients were female and 79 male. 49/143 (34.3%)
patients had surgically corrected CRHD, 35/143 (24.5%) patients a SRV of whom 10 patients
had congenitally corrected transposition of the great arteries and 25 patients d-transposition
of the great arteries after atrial switch operation, 43/143 (30.1%) patients a single ventricle
physiology with Fontan palliation (FONT) and 16/143 (11.2%) patients a non-corrected cya-
notic heart defect or Eisenmenger physiology (EIS) (S1 Dataset). Follow-up investigations
were made with special emphasis on the occurrence of adverse cardiac events such as clinical
signs of overt heart failure including pleural effusions, ascites or significant peripheral edema
with weight gain as well as the occurrence of supraventricular arrhythmias or atrial fibrillation.
At each follow-up visit, a structured history and physical exam, a 12-lead surface electrocardio-
gram, measurement of blood pressure and transcutaneous oxygen saturation at rest and con-
ventional two-dimensional echocardiography were performed in all patients. Moreover,
venous blood was drawn for routine laboratory tests and blood sampling in all patients after
echocardiography. Blood samples of patients were compared to those of 26 healthy subjects
with a mean age of 30.8 ± 15.3 years (range 12–61 years) (S1 Dataset). The study complies with
the Declaration of Helsinki and was approved by the local ethics committee, specifically the
Saarland medical association ethical board. All participants or their guardians gave written
and informed consent before enrolment.
Conventional two-dimensional echocardiography
Two-dimensional echocardiography was performed using a Vivid 9 ultrasound system
(GE Healthcare, Horten, Norway) with a transducer operating at 3.5 MHz. Apical 4-chamber
views were acquired for the planimetric calculation of the ejection fraction (EF) as well as end-
systolic and enddiastolic volumes of the systemic ventricle according to the modified Simp-
son’s method [20]. Pulsed-wave Doppler echocardiography was performed to obtain the
outflow pattern above the aortic valve to measure velocity time integral (VTI). Continuous-
wave Doppler was used to estimate pressure gradients across the aortic or pulmonary valve.
Colored Doppler flow was used to assess the severity of regurgitation across the systemic atrio-
ventricular and aortic valve.
Biochemical analyses
Each venous blood sample was centrifuged and plasma removed, allocated and frozen at -80˚C
before analysis. NT-proBNP was analyzed using an electrochemiluminescence sandwich
immunoassay (Cobas1 proBNP II, Roche Diagnostics, Basel, Switzerland) on the Elecsys1
2010 analyzer. Levels of hArg were measured by high-performance liquid chromatography
with solid phase extraction and precolumn derivatization as previously described [21].
Within-day coefficients of variation were 4.7% (1.21 μmol/L) and 2.2% (3.53 μmol/L). Liver
function tests and creatinine measurements were performed using standard laboratory
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techniques. All biochemical analyses were performed by investigators blinded to the clinical
data of the patients.
Data analysis
Clinical data of the patients were collected from medical records. The two-dimensional echo-
cardiographic and Doppler images were stored digitally and analysed on an Echopac server
(Echopac Version 6.1.0, GE Healthcare). Echocardiographic data sets were assessed by investi-
gators blinded to the laboratory results.
Patients with adverse cardiac events were categorized into 3 subgroups: (1) patients with
sporadic new-onset supraventricular arrhythmias, (2) patients with recurrent supraventricular
arrhythmias or permanent atrial fibrillation and (3) patients who died or presented with overt
heart failure including failure of the Fontan circuit during follow-up.
Statistical analysis
Data were analysed using standard statistical software (SPSS version 19; SPSS Inc., Chicago,
Illinois). Continuous variables are expressed as mean ± standard deviation or median and
interquartile range as appropriate. Differences between unpaired groups were analysed using a
Mann-Whitney-U test for continuous variables and a chi-square test (or Fisher exact test, if
numbers were small) for nominal variables. Correlations were evaluated using Spearman’s
regression coefficient. Differences between paired groups were analysed using a Wilcoxon-
signed-rank test for continuous variables. Receiver-operating characteristic curve (ROC)
analysis was used in a univariate approach for the prediction of adverse cardiac events. A two-
tailed p-value <0.05 was considered statistically significant.
Results and discussion
Results
Clinical, echocardiographic and routine laboratory data. During follow-up, a total of 33
adverse cardiac events occurred in 30/143 (21.0%) patients: 4 patients died (1 patient due to
sudden cardiac death, 3 patients due to progressive heart failure), 15 patients presented with
overt heart failure or a failing Fontan circuit, 6 patients had sporadic new-onset supraventricu-
lar arrhythmias, 8 patients had recurrent supraventricular arrhythmias or permanent atrial
fibrillation indicating high atrial arrhythmic burden. Of the 30 patients, 4 had CRHD (13.3%),
8 SRV (26.7%), 12 FONT (40%) and 6 EIS (20%) as underlying CHD (S1 Dataset). Characteris-
tics of patients with and without adverse cardiac events are shown in Table 1.
In patients with adverse cardiac events, NYHA class was significantly higher, mean EF of
the systemic ventricle and VTI above the aortic valve were significantly lower as compared to
patients without any cardiac event during follow-up. Furthermore, concentrations of γGT and
NT-proBNP were significantly elevated whereas hArg levels were significantly reduced in
patients with adverse cardiac events. Median creatinine levels and estimated glomerular filtra-
tion rate were normal in both groups indicating no relevant renal dysfunction.
Homoarginine concentrations. Homoarginine levels ranged from 0.43 to 4.29 μmol/l
with a median of 1.5 μmol/l (1.12–1.98 μmol/l) in the patient group. In general, median hArg
levels were reduced in patients compared to healthy controls showing a median hArg level of
1.70 μmol/l (1.39–2.08 μmol/l; p = 0.051). A marked and significant reduction of hArg levels,
however, was seen in patients after Fontan palliation with a median of 1.27 μmol/l (0.84–
1.6 μmol/l) and in those with Eisenmenger physiology with a median of 0.99 μmol/l (0.79–
1.47 μmol/l) (p<0.001) (Fig 1) (S1 Dataset).
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Median hArg levels were also significantly reduced in patients with adverse cardiac events
compared to patients without (p<0.001) (Table 1). Moreover, differences in hArg levels were
found corresponding to the severity of adverse cardiac events with the lowest hArg levels
found in patients prior to death or overt heart failure (Fig 2).
Levels of hArg were weakly related to NT-proBNP levels (r = -0.285; p = 0.001). Relations of
both biomarkers to clinical, echocardiographic and laboratory parameters are given in Table 2.
NT-proBNP levels were significantly related to age at follow-up, NYHA functional class,
trans-cutaneous oxygen saturation, ejection fraction and endsystolic volume of the systemic
ventricle, VTI above the aortic valve, estimated glomerular filtration rate, albumin and γGT
levels. In contrast, hArg levels were only significantly related to NYHA functional class, trans-
cutaneous oxygen saturation and γGT levels but not to measures of systolic ventricular func-
tion or estimated glomerular filtration rate (S1 Dataset).
Repeated measurements of hArg and NT-proBNP concentrations were obtained in 41 of
143 patients of whom 8 patients presented with and 33 patients without adverse cardiac event.
In the 8 patients with adverse cardiac event, median hArg levels decreased significantly from
1.43 μmol/l to 0.97 μmol/l prior to the event (p = 0.012) but also a significant increase in
median NT-proBNP levels from 880.2 pg/ml to 1021.9 pg/ml was seen (p = 0.017). In the 33
Table 1. Characteristics of patients with and without adverse cardiac events#.
Variables All patients Patients without adverse cardiac
events
Patients with adverse cardiac
events
p-value*
(n = 143) (n = 113) (n = 30)
Age at follow-up (years) 27.5 ± 12.0 26.5 ± 10.8 31.1 ± 15.5 ns
Number of patients with Fontan palliation or
Eisenmenger physiology
59/143 (41%) 41/113 (36.3%) 18/30 (60%) 0.02
NYHA functional class 1.6 ± 0.7 1.4 ± 0.5 2.3 ± 0.9 < 0.001
Systolic blood pressure (mmHg) 121.4 ± 14.7 121.9 ± 13.6 119.9 ± 18.3 ns
Diastolic blood pressure (mmHg) 70.8 ± 9.2 71.2 ± 9.2 69.1 ± 9.2 ns
Transcutaneous oxygen saturation at rest (%) 94.5 ± 5.8 95.5 ± 4.4 90.5 ± 8.4 < 0.001
Ejection fraction of SV (%) 50.9 ± 11.3 53.0 ± 9.2 43.0 ± 14.9 < 0.001
Enddiastolic volume of SV (ml) 110.0 ± 43.7 106.3 ± 39.9 123.8 ± 54.4 ns
Endsystolic volume of SV (ml) 55.8 ± 32.0 50.9 ± 24.4 74.3 ± 47.6 0.004
VTI above aortic valve (cm) 24.0 ± 5.0 24.7 ± 4.5 21.4 ± 5.9 0.004
Creatinine (mg/dl) 0.81 0.80 0.84 ns
(0.70–0.95) (0.70–0.94) (0.59–1.1)
Estimated GFR (ml/min) 102.1 103.4 96.3 ns
(90.4–118.9) (92.6–119.6) (82.7–118.3)
γGT (U/l) 41.0 34.0 72.0 < 0.001
(24.0–71.0) (22.0–61.0) (55.5–102.3)
Albumin (g/l) 47.0 47.0 45.0 0.034
(44.0–49.0) (45.0–49.0) (40.8–50.0)
NT-proBNP (pg/ml) 164.7 136.7 651.0 < 0.001
(77.4–501.1) (68.9–275.8) (275.1–1326.2)
Homoarginine (μmol/l) 1.5 1.63 1.03 < 0.001
(1.12–1.98) (1.28–2.12) (0.78–1.36)
CHD, congenital heart disease; NYHA, New York Heart Association; SV, systemic ventricle; VTI, velocity time integral; GFR, glomerular filtration rate
# Mean ± standard deviation or median (interquartile range) are used
* Patients with compared to those without adverse cardiac events
https://doi.org/10.1371/journal.pone.0184333.t001
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Fig 1. Boxplots displaying homoarginine levels in healthy controls and patients with various types of
complex heart defects. CRHD, corrected congenital right heart disease; SRV, systemic right ventricle;
FONT, Fontan palliation; EIS, Eisenmenger physiology or unrepaired cyanotic heart defect.
https://doi.org/10.1371/journal.pone.0184333.g001
Fig 2. Boxplots demonstrating homoarginine levels in patients with different adverse cardiac events.
SVT, supraventricular tachycardia; AF, atrial fibrillation.
https://doi.org/10.1371/journal.pone.0184333.g002
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patients without adverse cardiac event, no difference in median hArg or NT-proBNP levels
was detected. However, in 11 of these 33 patients, a significant rise of NT-proBNP levels from
a median baseline level of 381.1 pg/ml to a median level of 747.1 pg/ml (p = 0.003) was
observed without acute or subsequent deterioration of the clinical status of the patients, clinical
signs of overt heart failure, new onset arrhythmias or renal function changes. In contrast, hArg
levels were stable in these patients and did not differ significantly (median baseline level of
1.77 μmol/l vs 1.78 μmol/l, p = 0.213).
Homoarginine and adverse cardiac events. ROC curve analysis was used to identify pre-
dictors of adverse cardiac events in general (Fig 3) as well as predictors of death due to progres-
sive heart failure or occurrence of overt heart failure in particular (Fig 4).
Table 2. Relation of hArg and NT-proBNP with different variables*.
hArg NT-proBNP
r p-value r p-value
Age at follow-up 0.090 ns 0.488 < 0.001
NYHA functional class -0.294 < 0.001 0.551 < 0.001
Systolic blood pressure 0.194 0.020 -0.052 ns
Diastolic blood pressure 0.274 0.001 -0.019 ns
Transcutaneous oxygen saturation at rest 0.487 < 0.001 -0.212 0.011
Ejection fraction of SV 0.075 ns -0.559 < 0.001
Enddiastolic volume of SV -0.035 ns 0.083 ns
Endsystolic volume of SV -0.035 ns 0.303 < 0.001
VTI above aortic valve 0.152 ns -0.293 < 0.001
Creatinine -0.011 ns 0.134 ns
Glomerular filtration rate 0.069 ns -0.288 0.001
Albumin 0.155 ns -0.223 0.007
γGT -0.306 < 0.001 0.274 0.001
hArg, homoarginine; NYHA, New York Heart Association; SV, systemic ventricle; VTI, velocity time integral
*Spearman rank correlation
https://doi.org/10.1371/journal.pone.0184333.t002
Fig 3. Receiver-operating characteristic (ROC) curves comparing sensitivity and specificity of hArg and NT-proBNP levels in predicting
adverse cardiac events in general. AUC, area under the curve.
https://doi.org/10.1371/journal.pone.0184333.g003
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The most significant predictors of adverse cardiac events in patients with complex CHD
were hArg levels (AUC 0.837, p<0.001, CI 0.726–0.947), γGT levels (AUC 0.804, p<0.001, CI
0.694–0.914), NYHA class (AUC 0.800, p<0.001, CI 0.672–0.928), NT-proBNP levels (AUC
0.780, p<0.001, CI 0.669–0.891), albumin levels (AUC 0.720, p = 0.005, CI 0.544–0.897) and
ejection fraction of the systemic ventricle (AUC 0.667, p = 0.024, CI 0.507–0.826), respectively.
The optimal cut-off of hArg for the prediction of adverse cardiac events in general was calcu-
lated to be 1.22 μmol/l with a sensitivity of 84.2%, specificity of 77.4%, positive predictive value
of 38.1%, negative predictive value of 96.7% and overall accuracy of 78.4%. The optimal cut-off
of NT-proBNP for the prediction of adverse cardiac events was calculated to be 341.2 pg/ml
with a sensitivity of 73.7%, specificity of 77.4%, positive predictive value of 35.0%, negative pre-
dictive value of 94.7% and overall accuracy of 76.9%.
Death due to progressive heart failure or the occurrence of overt heart failure were best
predicted by NYHA class (AUC 0.945, p<0.001, CI 0.898–0.992), hArg levels (AUC 0.911,
p<0.001, CI 0.850–0.971), NT-proBNP levels (AUC 0.876, p<0.001, CI 0.791–0.962), albumin
levels (AUC 0.743, p = 0.003, CI 0.551–0.935), γGT levels (AUC 0.732, p = 0.003, CI 0.579–
0.885), EF of the systemic ventricle (AUC 0.723, p = 0.004, CI 0.560–0.886) and VTI above the
aortic valve (AUC 0.720, p = 0.007, CI 0.550–0.889), respectively. The optimal cut-off of hArg
for the prediction of death due to progressive heart failure or the occurrence of overt heart fail-
ure was calculated to be 1.08 μmol/l with a sensitivity of 93.8%, specificity of 85.3%, positive
predictive value of 46.9%, negative predictive value of 99.0% and overall accuracy of 86.4%.
The optimal cut-off of NT-proBNP was calculated to be 341.2 pg/ml with a sensitivity of
87.5%, specificity of 78.5%, positive predictive value of 35.9%, negative predictive value of
97.8% and overall accuracy of 79.6%. More detailed information is given in Table 3.
Discussion
Recent studies have demonstrated the potential diagnostic and prognostic utility of hArg in
patients with chronic left heart failure [15,22]. While measurements of symmetrical and asym-
metrical dimethylarginine have been performed to assess their diagnostic utility in precisely
defined subsets of CHD patients [17,18] this is, to our knowledge, the first study investigating
hArg levels in a heterogeneous group of patients with complex CHD including analysis of
adverse cardiac events in order to assess its prognostic utility.
Fig 4. Receiver-operating characteristic (ROC) curves comparing sensitivity and specificity of hArg and NT-proBNP levels in predicting
death due to progressive heart failure or occurrence of overt heart failure. AUC, area under the curve.
https://doi.org/10.1371/journal.pone.0184333.g004
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Homoarginine in different patient groups. Our study demonstrates that hArg levels
differ significantly between healthy controls and CHD patients, in particular those with uni-
ventricular physiology after Fontan palliation and unrepaired cyanotic malformations or
Eisenmenger physiology with the latter showing significantly decreased hArg concentrations
(Fig 1). This result is not surprising since endothelial dysfunction is frequently present in these
subsets of CHD patients. Endothelial dysfunction also plays an important role in the mecha-
nism of a failing Fontan circuit due to endothelin mediated elevation of pulmonary vascular
resistance [23–25] or in patients with cyanotic CHD via downregulation of NO synthase in
cardiomyocytes resulting in reduced production/ release of NO [26]. If hArg also plays a spe-
cific role in this setting remains unclear, however, it is known to be involved in NO metabo-
lism and positively related to endothelial function [10,11].
In our study population, lower hArg levels were also found in patients with adverse cardiac
events as compared to those without any cardiac event (Table 1). Moreover, hArg levels
decreased significantly with the severity of adverse cardiac events (Fig 2) with the lowest levels
found in patients prior to death or overt heart failure indicating the worst scenario of adverse
cardiac events. Also, hArg levels were lower in patients with recurrent supraventricular
arrhythmias/ permanent atrial fibrillation reflecting altered or even worsening systemic ven-
tricular function and disease progression. It is of note that most of the patients (60%) exhibit-
ing adverse cardiac events in our study had a single ventricle physiology after Fontan palliation
or Eisenmenger physiology/ unrepaired cyanotic CHD indicating that the presence of endo-
thelial dysfunction may contribute to the occurrence of adverse cardiac events aside from the
thromboembolic complications typically known in these patients [27,28]. The rather low per-
centage of adverse cardiac events in the other subsets of CHD patients (i.e. patients with
repaired CRHD or SRV) may be due to the fact that the majority of these patients were in a
good clinical status at the time of enrolment and also remained clinically stable during the fol-
low-up period. This might also be the reason why hArg levels in these subsets of patients did
not differ significantly to healthy controls (Fig 1).
Association of hArg with other variables. hArg levels were only weakly related to NT-
proBNP levels reflecting that both biomarkers represent different pathophysiological path-
ways. While a strong correlation was found between NT-proBNP levels and measures of sys-
tolic ventricular function, hArg levels were not related to these measures. Moreover, hArg
showed a rather weak correlation to NYHA functional class. These results are in accordance
with a previous study in patients with chronic left heart failure revealing hArg as an indepen-
dent marker from NT-proBNP and NYHA stages [15].
However, a significant association of hArg with transcutaneous oxygen saturation was
found which is often reduced in patients after Fontan palliation or with Eisenmenger
Table 3. Comparison of different parameters in predicting death due to progressive heart failure or the occurrence of overt heart failure.
Variables Optimal cut-off value Sensitivity Specificity PPV NPV Overall accuracy
Homoarginine 1.08 μmol/l 93.8% 85.3% 46.9% 99.0% 86.4%
NT-proBNP 341.2 pg/ml 87.5% 78.5% 35.9% 97.8% 79.6%
NYHA functional class 2.5 76.5% 96.6% 76.5% 96.6% 94.0%
Ejection fraction of SV 37.1% 50.0% 94.8% 57.1% 93.2% 89.3%
VTI above aortic valve 19.7 cm 57.1% 86.1% 33.3% 94.3% 83.0%
γGT 57.5 U/l 75.0% 71.9% 27.3% 95.3% 72.3%
Albumin 43.5 g/l 66.7% 87.5% 47.6% 93.9% 84.5%
PPV, positive predictive value; NPV, negative predictive value; NYHA, New York Heart Association; SV, systemic ventricle; VTI, velocity time integral
https://doi.org/10.1371/journal.pone.0184333.t003
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physiology/ unrepaired cyanotic CHD. It is known from previous studies that chronic hypoxia
leads to alterations in endothelial function [26,29] thus supporting the hypothesis of hArg
being involved in NO metabolism. In addition, the enzyme L-arginine:glycine amidinotrans-
ferase, which is the major hArg producer, has been shown to be linked to local creatine phos-
phate synthesis [30]. Thus, one could hypothesize that there is some association between hArg,
L-arginine:glycine amidinotransferase and tissue hypoxia as the latter doubtlessly impacts on
local energy metabolism.
Prediction of death and overt heart failure. According to ROC analysis, the 3 most sig-
nificant predictors for the occurrence of overt heart failure or death due to progressive heart
failure were found to be NYHA class, hArg and NT-proBNP levels with a slightly higher AUC
for hArg than for NT-proBNP (Fig 4). These findings demonstrate that NYHA class still is a
strong and reliable predictor for overt heart failure despite its subjective aspect of classification
but that hArg levels may also predict severe adverse cardiac events and especially the occur-
rence of overt heart failure as reliably as or even better than NT-proBNP levels. Moreover,
repeated measurements (although small in number) demonstrated significantly declining
hArg levels prior to the occurrence of overt heart failure or death due to progressive heart fail-
ure indicating that serial measurements of hArg levels may identify patients at risk for these
severe adverse cardiac events. Furthermore, a significant rise of NT-proBNP levels was
observed in some study patients without acute or subsequent deterioration of their clinical sta-
tus or cardiac function whereas hArg levels remained stable in this setting. Thus, hArg levels
seem to be more stable in the long run than NT-proBNP levels what is not surprising because
hArg levels do not reflect rapid load-dependent cardiac changes but rather long-standing met-
abolic alterations. All these results indicate that hArg levels might also be of prognostic value
in patients with complex CHD.
Conclusions
In patients with complex CHD, hArg levels can predict adverse cardiac events as reliably as or
even better than NT-proBNP levels and thus might also be of prognostic value in this subset of
patients. In contrast to NT-proBNP, hArg levels seem to reflect long-standing metabolic alter-
ations rather than rapid load-dependent cardiac changes.
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